Robert McWhirter Medx Health Corp. MDX-X BUY Feb 20, 2018

Their numbers were up 13%. They have a device that looks at moles for Melanoma. They are now focusing on health and safety for workers. There is a pilot going on with Loblaw’s.

This company's product is truly revolutionary, because it looks millimetres below the skin’s surface to actually see what is going on. They take a picture, send it on a secure basis to a dermatologist, who then sees the situation. A year ago, they retooled their laser therapy device, and that is selling quite well. They are working on some improved software to make it easier on a "plug-and-play" basis for the actual melanoma detection device. A great product. The company needs sales of about $1.8 million to break even, and they have $9 million of tax loss carry forward. His expectation is that by Q3 of 2018, they will be profitable. He owns warrants on this.

He thinks there is good opportunity for this medical device manufacturer with the arrival of a new CEO. Note: His wife works as a consultant for this company.

They have a new President and CEO. They released a new web site. They replace needles for dental work with laser. On the innovative side, their Durham product gives totally secure examination of a mole with results in 72 hours. The long awaited approval of the devices in Mexico is expected soon. There are expected global partnerships. He thinks there are really good opportunities for them.